Protagonist Therapeutics IncPTGX
Price$139.19

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $74.1M-83.0% YoYTTM through 31 Mar 2026
Net Income $82.9M-69.9% YoYTTM through 30 Jun 2026
Free Cash Flow $130.6MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin80.9%
Operating Margin78.8%
Net Margin111.9%

Returns

9.9%ROE
9.4%ROA

Balance Sheet Health

Current Ratio21.71x
Cash & Equivalents$420.1M

Quality Metrics

Altman Z-Score128.87
Piotroski F-Score4 / 9
FCF Margin176.3%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $46M
Diluted EPS$1.03TTM
'20'21'22'23'24'25
FY2025: $-2.05

Dividend

No dividend

Capital Allocation

Capex Intensity0.8%

Segment Performance

SegmentRevenueYoYOutlook
Peptide Therapeutics$46M-89.4%
View details

Highly variable and dependent upon the timing of regulatory and sales milestones achieved under JNJ and Takeda agreements.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.